Related search

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma

Frontiers in Oncology
Cancer ResearchOncology
2019English

Combined Modality Therapy Results in Improved Overall Survival for Angiosarcoma

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2016English

Optimizing Combination Dabrafenib and Trametinib Therapy in BRAF Mutation-Positive Advanced Melanoma Patients: Guidelines From Australian Melanoma Medical Oncologists

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2016English

Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma

Oncologist
Cancer ResearchMedicineOncology
2013English

Verbessertes Gesamtüberleben Mit Der Kombination Dabrafenib Und Trametinib

hautnah
2015English

BRAF-mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade With Dabrafenib, Trametinib, and Panitumumab in Patients With Colorectal Cancer

Clinical Cancer Research
Cancer ResearchOncology
2020English

Granulomatosis With Polyangiitis in a Patient Treated With Dabrafenib and Trametinib for BRAF V600E Positive Lung Adenocarcinoma

BMC Cancer
Cancer ResearchOncologyGenetics
2020English

Potassium Iodide in Successful Treatment of Erythema Nodosum‐like Lesions Induced by Combination Therapy With Dabrafenib and Trametinib

Journal of Dermatology
DermatologyMedicine
2019English

Combined Modality Therapy Improves Overall Survival for Angiosarcoma

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy